Basilea Pharmaceutica AG/Fr. BSLN
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Basilea Pharmaceutica AG
Basilea Pharmaceutica AG operates within the biopharmaceutical industry, focusing on the research, development, and commercialization of innovative medicines to meet medical needs in the areas of infectious diseases and oncology. The company's core products include anti-infective treatments such as Cresemba, an antifungal for invasive aspergillosis and mucormycosis, and Zevtera, a broad-spectrum antibiotic for bacterial infections. Founded in 2000 as a spin-off from Roche, the company is headquartered in Basel, Switzerland. Basilea's unique strategic approach involves enhancing its pipeline through collaborations and licensing agreements, which strengthens its position in the niche market of bacterial resistance and other medical areas with high unmet needs. The company has a significant presence in Europe, the United States, and Asia, expanding its commercial footprint globally.
- Ticker
- Fr. BSLN
- Sector
- Health
- Primary listing
- XSWX
- Employees
- 200
- Headquarters
- Allschwil, Switzerland
- Website
- www.basilea.com
BSLN Metrics
BasicAdvanced
CHF 879M
17.73
CHF 4.01
0.43
-
Price and volume
Market cap
CHF 879M
Beta
0.43
52-week high
CHF 75.80
52-week low
CHF 44.70
Average daily volume
30K
Financial strength
Current ratio
6.596
Quick ratio
5.811
Long term debt to equity
0.501
Total debt to equity
0.514
Interest coverage (TTM)
21.08%
Profitability
EBITDA (TTM)
60.92
Gross margin (TTM)
38.51%
Net profit margin (TTM)
21.17%
Operating margin (TTM)
24.20%
Effective tax rate (TTM)
10.72%
Revenue per employee (TTM)
CHF 1,240,000
Management effectiveness
Return on assets (TTM)
13.69%
Return on equity (TTM)
39.46%
Valuation
Price to earnings (TTM)
17.73
Price to revenue (TTM)
3.536
Price to book
5.41
Price to tangible book (TTM)
5.42
Price to free cash flow (TTM)
15.874
Free cash flow yield (TTM)
6.30%
Free cash flow per share (TTM)
4.479
Growth
Revenue change (TTM)
4.74%
Earnings per share change (TTM)
-26.73%
3-year revenue growth (CAGR)
12.23%
10-year revenue growth (CAGR)
15.65%
3-year earnings per share growth (CAGR)
-3.53%
10-year earnings per share growth (CAGR)
-3.71%
What the Analysts think about BSLN
Analyst ratings (Buy, Hold, Sell) for Basilea Pharmaceutica AG stock.
Analyst projections of the future price of Basilea Pharmaceutica AG stock.
Bulls say / Bears say
Basilea sharply raised its 2026 outlook: operating profit is now expected to reach CHF 115 million, up from CHF 51.5 million in 2025, on revenue of about CHF 310 million. The higher forecast points to a strong near-term earnings step-up. (GlobeNewswire)
Cresemba continues to provide a growing commercial base: partner sales rose 27% to USD 782 million in the year to March 2026. That growth supports royalties and gives Basilea funds to invest in its pipeline. (Basilea)
The late-stage pipeline has a clearer path forward: regulators’ feedback allowed Basilea to plan one phase 2/3 study for ceftibuten-ledaborbactam, without a separate confirmatory phase 3 trial. The company also says fosmanogepix phase 3 studies are progressing towards 2028 readouts. (GlobeNewswire)
Cresemba remains a key source of income, leaving Basilea exposed to generic competition as exclusivity expires in major markets. An analyst report expects EU generic entry in 2028, following the expected 2027 loss of exclusivity. (Edison Group)
The pipeline offers no near-term replacement for Cresemba: fosmanogepix phase 3 results are expected in 2028, while the ceftibuten-ledaborbactam study is due to start in mid-2027. Both programmes still face clinical and regulatory execution risk before they can generate sales. (GlobeNewswire)
Part of the raised 2026 outlook depends on milestone income, which is now forecast at CHF 65 million rather than CHF 35 million. Such payments can be lumpy, so the forecast may be less dependable than growth from recurring sales and royalties. (GlobeNewswire)
Data summarised monthly by Lightyear AI. Last updated on 27 Oct 2026.
BSLN Financial Performance
Revenues and expenses
BSLN Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing BSLN
AllUSDEURGBP
Fund name | Fund size | Fr. BSLN weighting |
|---|---|---|
Xtrackers MSCI Europe Small Cap£XXSC | $3.6B | 0.07% |
Xtrackers MSCI Europe Small Cap€DX2J | $3.6B | 0.07% |
iShares MSCI World Small Cap€IUSN | $9B | 0.01% |
iShares MSCI World Small Cap$WSML | $9B | 0.01% |
iShares MSCI World Small Cap£WLDS | $9B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.